Zacks Investment Research upgraded shares of AC Immune (NASDAQ:ACIU) from a sell rating to a hold rating in a report released on Monday morning.
According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “
Separately, BidaskClub raised AC Immune from a buy rating to a strong-buy rating in a research note on Friday, January 26th.
AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. equities research analysts forecast that AC Immune will post -0.57 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Belpointe Asset Management LLC purchased a new position in AC Immune during the third quarter worth about $571,000. Janney Montgomery Scott LLC purchased a new position in AC Immune during the third quarter worth about $134,000. Wells Fargo & Company MN purchased a new position in AC Immune during the third quarter worth about $111,000. Finally, Goldman Sachs Group Inc. purchased a new position in AC Immune during the second quarter worth about $127,000. Hedge funds and other institutional investors own 17.12% of the company’s stock.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.